/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. OncLive® On Air
  2. S18 Ep40: INCB161734 Holds Potential Significance for KRAS G12D–Mutated mPDAC Management
S18 Ep40: INCB161734 Holds Potential Significance for KRAS G12D–Mutated mPDAC Management

S18 Ep40: INCB161734 Holds Potential Significance for KRAS G12D–Mutated mPDAC Management

OncLive® On Air · Sep 23, 2026

INCB161734, a selective KRAS G12D inhibitor, shows high efficacy and a strong safety profile, poised to reshape first-line pancreatic cancer therapy.

Selective KRAS G12D Inhibitors' Key Advantage is Enabling First-Line Chemo Combinations

INCB161734's high selectivity for the G12D mutation avoids the toxicities common in pan-RAS inhibitors. This superior safety profile is a key strategic advantage, as it allows the drug to be combined with standard first-line chemotherapy, a feat that is difficult for less selective agents.

S18 Ep40: INCB161734 Holds Potential Significance for KRAS G12D–Mutated mPDAC Management thumbnail

S18 Ep40: INCB161734 Holds Potential Significance for KRAS G12D–Mutated mPDAC Management

OncLive® On Air·2 months ago

KRAS G12D Inhibitors Will Create Two Distinct Treatment Paths for Pancreatic Cancer

The advent of selective G12D inhibitors will fundamentally split the treatment paradigm for pancreatic cancer. Patients with G12D mutations will likely receive these inhibitors combined with chemo upfront, while patients with other RAS mutations will follow a different therapeutic sequence.

S18 Ep40: INCB161734 Holds Potential Significance for KRAS G12D–Mutated mPDAC Management thumbnail

S18 Ep40: INCB161734 Holds Potential Significance for KRAS G12D–Mutated mPDAC Management

OncLive® On Air·2 months ago

DAWN-303 Trial Design Positions G12D Inhibitor as Long-Term Maintenance Therapy

The trial's design strategically allows for chemotherapy to be reduced or stopped due to toxicity while the patient continues on the G12D inhibitor. This positions the experimental drug not just as an add-on, but as a potential long-term maintenance backbone for treatment.

S18 Ep40: INCB161734 Holds Potential Significance for KRAS G12D–Mutated mPDAC Management thumbnail

S18 Ep40: INCB161734 Holds Potential Significance for KRAS G12D–Mutated mPDAC Management

OncLive® On Air·2 months ago

High Response Rates from G12D Inhibitor Combos May Expand Use to Earlier, Resectable Cancers

The speaker predicts that if the G12D inhibitor and chemotherapy combination proves successful in the metastatic setting, its high response rate and safety profile will make it a compelling option for earlier stages of the disease, such as in neoadjuvant settings for resectable cancers.

S18 Ep40: INCB161734 Holds Potential Significance for KRAS G12D–Mutated mPDAC Management thumbnail

S18 Ep40: INCB161734 Holds Potential Significance for KRAS G12D–Mutated mPDAC Management

OncLive® On Air·2 months ago